Rome, 27 February – Pharmaceutical spending under agreements and for direct purchases amounted to 14,878.2 million euros, with an absolute difference with respect to the total resources of 14.85% (13,842.2 million) equal to +1,036 million, corresponding to a percentage incidence on the National Health Fund of 15.96%. This deficit is calculated by excluding from the pharmaceutical expenditure the estimate of the resources allocated with the funds for innovative oncological and non-oncological medicines. And what emerges from the Aifa monitoring on the 
pharmaceutical expenditure in the period January-October 2017.
Pharmaceutical expenditure for direct purchases amounted to 7,819 million euros, with an incidence on the National Health Fund of 8.39%, equal to a deficit with respect to planned expenditure of 1,396 million. Pharmaceutical expenditure for direct distribution of category A stood at 3,947 million, showing a decrease, compared to the previous year, of 776.9 million (-16.4%).
The trend of pharmaceutical spending paid by the NHS is different which, net of discounts, total sharing (regional tickets and sharing of the reference price) and the pay-back paid to the Regions by pharmaceutical companies, amounted to 6,789 million euros, recording a decrease compared to the previous year of 54 million euros (-0.8%).
In particular, there is a surplus of 360.3 million euro with respect to the planned ceiling for agreed spending. Consumption also decreased, expressed in the number of prescriptions (484 million), equal to -0.6% compared to 2016, while the incidence of the ticket increased by 0.7% (9 million euro). At the same time, an increase of +3.4% in daily doses (+697.6 million) was observed.
February 27, 2018 – Regioni.it
Related news: AIFA. Monitoring of National and Regional Pharmaceutical Expenditure (January / October 2017)
Non-prescription drugs: in 2017 consumption decreased by 4.8%
